AMLX
Amylyx Pharmaceuticals, Inc. NASDAQ Listed Jan 7, 2022$16.06
After hrs
$16.06
+0.00%
Mkt Cap $1.3B
52w Low $4.20
82.3% of range
52w High $18.61
50d MA $15.38
200d MA $13.16
P/E (TTM)
-10.5x
EV/EBITDA
-6.4x
P/B
5.0x
Debt/Equity
0.0x
ROE
-47.4%
P/FCF
-9.3x
RSI (14)
—
ATR (14)
—
Beta
-0.21
50d MA
$15.38
200d MA
$13.16
Avg Volume
1.1M
About
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also develop…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.31 | -0.30 | +3.2% | 14.11 | -0.3% | +6.7% | -0.1% | -1.8% | +1.4% | +6.2% | — |
| Nov 6, 2025 | AMC | -0.43 | -0.37 | +14.0% | 12.46 | +0.8% | -1.2% | -2.2% | +1.8% | -1.0% | -0.3% | — |
| Aug 7, 2025 | AMC | -0.44 | -0.46 | -4.5% | 7.84 | -0.3% | -2.6% | -0.3% | +4.6% | +5.9% | +7.3% | — |
| May 8, 2025 | AMC | -0.45 | -0.42 | +6.7% | 4.58 | -1.5% | +0.7% | +0.4% | -2.0% | -5.0% | -1.3% | — |
| Mar 4, 2025 | AMC | -0.49 | -0.55 | -12.2% | 3.01 | +0.0% | +11.6% | +19.9% | +28.6% | +15.9% | +23.9% | — |
| Nov 7, 2024 | AMC | -0.47 | -0.53 | -12.8% | 6.54 | +4.0% | +2.4% | +7.5% | -4.6% | -13.1% | -23.2% | — |
| Aug 8, 2024 | AMC | -0.38 | -0.73 | -92.1% | 1.80 | +1.1% | +5.6% | +10.0% | +10.6% | +18.3% | +20.0% | — |
| May 9, 2024 | AMC | 0.24 | -0.46 | -291.7% | 1.89 | -0.5% | -6.9% | -3.7% | -1.1% | -3.7% | -3.2% | — |
| Feb 22, 2024 | AMC | 0.23 | 0.07 | -69.6% | 18.54 | +1.0% | -4.8% | -5.3% | +2.5% | +5.6% | +1.7% | — |
| Nov 9, 2023 | AMC | 0.44 | 0.30 | -31.8% | 12.26 | +2.4% | +1.8% | +5.5% | +2.1% | +6.7% | -1.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Mizuho | Maintains | Outperform → Outperform | — | $16.88 | $17.05 | +1.0% | -3.4% | -7.6% | -5.2% | -5.2% | — |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.66 | $13.94 | +2.0% | +1.2% | -1.4% | -0.8% | -6.6% | +1.8% |
| Mar 19 | Guggenheim | Maintains | Buy → Buy | — | $13.79 | $13.98 | +1.4% | +1.9% | +0.1% | -1.9% | -0.9% | +0.3% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.07 | -0.3% | +6.7% | -0.1% | -1.8% | +1.4% | +6.2% |
| Feb 20 | BofA Securities | Maintains | Buy → Buy | — | $14.02 | $14.45 | +3.1% | -0.1% | -0.9% | +4.9% | +2.5% | +8.8% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.22 | $14.86 | +4.5% | +4.7% | +0.9% | -1.1% | -0.7% | -0.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.46 | $12.56 | +0.8% | -1.2% | -2.2% | +1.8% | -1.0% | -0.3% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $15.17 | $15.17 | +0.0% | -1.5% | +1.3% | +0.8% | -2.3% | -5.7% |
| Oct 16 | Baird | Maintains | Outperform → Outperform | — | $15.79 | $15.93 | +0.9% | -3.9% | -5.3% | -2.7% | -3.2% | -6.1% |
| Oct 3 | BofA Securities | Maintains | Buy → Buy | — | $13.29 | $13.56 | +2.0% | +1.0% | -4.5% | +1.5% | +1.4% | +8.9% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Amylyx Pharmaceuticals disclosed its strategic focus on endocrine and neurodegenerative disease therapies, signaling management's commitment to high-risk, high-reward drug development that could drive significant long-term value if successful.
Mar 24
8-K
Amylyx Pharmaceuticals, Inc. -- 8-K Filing
Amylyx Pharmaceuticals advanced its avexitide program for post-bariatric hypoglycemia and progressed its pipeline during 2025, demonstrating operational momentum for the clinical-stage biotech company.
Mar 3
Data updated apr 24, 2026 5:49pm
· Source: massive.com